Search Results - "Cagnoni, P."

Pharmacokinetic and Maximum Tolerated Dose Study of Micafungin in Combination with Fluconazole versus Fluconazole Alone for Prophylaxis of Fungal Infections in Adult Patients Undergoing a Bone Marrow or Peripheral Stem Cell Transplant by HIEMENZ, J, CAGNONI, P, SIMPSON, D, DEVINE, S, CHAR, N, KEIRNS, J, LAU, W, FACKLAM, D, BUELL, D

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Invasive Mycotic Infections Caused by Chaetomium perlucidum, a New Agent of Cerebral Phaeohyphomycosis by BARTON, M. A, SUTTON, D. A, VEVE, R, GUARRO, J, RINALDI, M, THOMPSON, E, CAGNONI, P. J, MOULTNEY, K, MADINGER, N. E

“…Article Usage Stats Services JCM Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Pharmacoeconomic Analysis of Liposomal Amphotericin B Versus Conventional Amphotericin B in the Empirical Treatment of Persistently Febrile Neutropenic Patients by CAGNONI, P. J, WALSH, T. J, TONG, K. B, PRENDERGAST, M. M, BODENSTEINER, D, HIEMENZ, S, GREENBERG, R. N, ARNDT, C. A. S, SCHUSTER, M, SEIBEL, N, YELDANDI, V

“…In a randomized, double-blind, comparative, multicenter trial, liposomal amphotericin B was equivalent to conventional amphotericin B for empirical antifungal…”
Get full text

Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients by MILLER, C. B, WALLER, E. K, CHAO, N. J, KLINGEMANN, H. G, DIGNANI, M. C, ANAISSIE, E. J, CAGNONI, P. J, MCSWEENEY, P, FLECK, P. R, FRUCHTMAN, S. M, MCGUIRK, J

“…The current study assessed renal function based on medical records in adult hematopoietic stem cell transplant (HSCT) recipients with proven or probable…”
Get full text

Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics by CAGNONI, P. J, MATTHES, S, DAY, T. C, BEARMAN, S. I, SHPALL, E. J, JONES, R. B

“…Interpatient variability in exposure to certain chemotherapy agents can influence patient outcome, particularly with high-dose chemotherapy. We evaluated the…”
Get full text

Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients by CAGNONI, Pablo J

“…Liposomal amphotercin B was compared with conventional amphotericin B for empirical antifungal therapy in febrile neutropenic patients in a randomized,…”
Get full text

White matter disease induced by high-dose chemotherapy: longitudinal study with MR imaging and proton spectroscopy by Brown, MS, Stemmer, SM, Simon, JH, Stears, JC, Jones, RB, Cagnoni, PJ, Sheeder, JL

“…The purpose of this study was to determine the time course for development of white matter changes induced by high-dose chemotherapy. Eight patients with…”
Get full text

Evaluation of the Predictive Value of Her-2/neu Overexpression and p53 Mutations in High-Risk Primary Breast Cancer Patients Treated With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation by NIETO, Y, CAGNONI, P. J, JONES, R. B, NAWAZ, S, SHPALL, E. J, YERUSHALMI, R, COOK, B, RUSSELL, P, MCDERMIT, J, MURPHY, J, BEARMAN, S. I

“…To ascertain the predictive value of Her-2/neu overexpression and p53 mutations, assessed by immunohistochemistry, in high-risk primary breast cancer (HRPBC)…”
Get full text

Acute pancreatitis during immunosuppression with tacrolimus following an allogeneic umbilical cord blood transplantation by NIETO, Y, RUSS, P, EVERSON, G, BEARMAN, S. I, CAGNONI, P. J, JONES, R. B, SHPALL, E. J

“…Tacrolimus is increasingly used for graft-versus-host disease (GVHD) prophylaxis and therapy in the allogeneic stem cell transplant (allo-SCT) setting…”
Get full text

High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: a phase I trial by Stemmer, S M, Cagnoni, P J, Shpall, E J, Bearman, S I, Matthes, S, Dufton, C, Day, T, Taffs, S, Hami, L, Martinez, C, Purdy, M H, Arron, J, Jones, R B

“…To determine the maximal-tolerated dose (MTD) of paclitaxel in combination with high-dose cyclophosphamide (CPA) and cisplatin (cDDP) followed by autologous…”
Get more information

High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer by Cagnoni, P J, Nieto, Y, Shpall, E J, Bearman, S I, Barón, A E, Ross, M, Matthes, S, Dunbar, S E, Jones, R B

“…To evaluate the feasibility of high-dose chemotherapy (HDC) with autologous hematopoietic progenitor-cell support (AHPCS) as part of combined modality therapy…”
Get more information

A Predictive Model for Relapse in High-Risk Primary Breast Cancer Patients Treated with High-Dose Chemotherapy and Autologous Stem-Cell Transplant by NIETO, Y, CAGNONI, P. J, SHPALL, E. J, XUESHENG XU, MURPHY, J, VREDENBURGH, J, CHAO, N. J, BEARMAN, S. I, JONES, R. B

“…High-dose chemotherapy (HDCT) is currently under evaluation for high-risk primary breast cancer (HRPBC), defined by extensive axillary nodal involvement or…”
Get full text

Topical transforming growth factor-β3 in the prevention or alleviation of chemotherapy-induced oral mucositis in patients with lymphomas or solid tumors by FONCUBERTA, M. C, CAGNONI, P. J, POUILLART, P, SCHREZENMEIER, H, EMMONS, R, THIEL, E, BRANDTS, C. H, MANDANAS, R, FIELDS, K, DERIGS, H. G, REED, E, SONIS, S. T, FAY, J, LEVEQUE, F

Get full text

Optic disc and retinal microvasculopathy after high-dose chemotherapy and autologous hematopoietic progenitor cell support by JOHNSON, D. W, CAGNONI, P. J, SCHOSSAU, T. M, STEMMER, S. M, GRAYEB, D. E. M, BARON, A. E, SHPALL, E. J, BEARMAN, S. I, MCDERMITT, J, JONES, R. B

“…The purpose of this study was to prospectively evaluate the retinal and optic nerve changes in patients undergoing high-dose chemotherapy (HDC) followed by…”
Get full text

High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes by BEARMAN, S. I, OVERMOYER, B. A, ROSS, M, JONES, R. B, BOLWELL, B. J, TAYLOR, C. W, SHPALL, E. J, CAGNONI, P. J, MECHLING, B. E, RONK, B, BARON, A. E, PURDY, M. H

“…Breast cancer patients with more than three involved axillary lymph have a high likelihood of relapse after adjuvant therapy. Early results of administration…”
Get full text

Phase II Trial of High-Dose Chemotherapy with Autologous Stem Cell Transplant for Stage IV Breast Cancer with Minimal Metastatic Disease by NIETO, Y, CAGNONI, P. J, SHPALL, E. J, MATTHES, S, BARON, A, JONES, R. B, BEARMAN, S. I

“…The purpose of this study was to assess the efficacy of high-dose chemotherapy (HDC) with autologous stem cell transplant in stage IV breast cancer patients…”
Get full text

Nonmyeloablative allogeneic hematopoietic stem cell transplantation for congenital sideroblastic anemia by Medeiros, B C, Kolhouse, J F, Cagnoni, P J, Ryder, J, Nieto, Y, Rabinovitch, R, Shpall, E J, Bearman, S I, Jones, R B, McSweeney, P A

“…Congenital sideroblastic anemia (CSA) is a dyserythropoietic disorder that leads to transfusion dependency and subsequent iron overload. Nonmyeloablative…”
Get full text

MR and proton spectroscopy of white matter disease induced by high-dose chemotherapy with bone marrow transplant in advanced breast carcinoma by Brown, MS, Simon, JH, Stemmer, SM, Stears, JC, Scherzinger, A, Cagnoni, PJ, Jones, RB

“…To determine whether the MR-detectable white matter changes associated with high-dose chemotherapy and bone marrow transplant in patients with advanced breast…”
Get full text

Intensive chemotherapy for progressive chronic lymphocytic leukemia administered early after a nonmyeloablative allograft by NIETO, Y, BEARMAN, S. I, SHPALL, E. J, JONES, R. B, CAGNONI, P. J, RABINOVITCH, R. A, MCSWEENEY, P. A

“…A 51-year-old patient with refractory CLL elected to participate in a trial of nonmyeloablative trans- plantation from an HLA-matched unrelated donor. He…”
Get full text

High-dose therapy with autologous hematopoietic cell support as salvage treatment for patients with breast cancer who have relapsed after previous high-dose chemotherapy by BEARMAN, S. I, VREDENBURGH, J. J, CAGNONI, P. J, SHPALL, E. J, NIETO, Y, ROSS, M, PETERS, W. P, JONES, R. B

“…Twenty-six patients with breast cancer who had relapsed after previously receiving high-dose chemotherapy and autologous hematopoietic cell support received a…”
Get full text